An Open, Not Controlled Study to Evaluate the Effect of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
Phase of Trial: Phase IV
Latest Information Update: 27 May 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 07 Nov 2009 Planned end date changed from Oct 2009 to Sep 2009 as reported by ClinicalTrials.gov.
- 04 Nov 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.